Oncology Clinical Trials - Global Strategic Business Report 2026: Secure Share Of A $6 Billion Revenue Surge By 2032 As Abbvie, Astrazeneca, ICON, Merck, And Roche Accelerate AI-Led Trials


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "Oncology Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global oncology clinical trials market was valued at US$11.2 billion in 2025 and is projected to reach US$17.2 billion by 2032, expanding at a compound annual growth rate of 6.4% during the forecast period. Market growth is being supported by rising cancer incidence, advances in genomics and molecular biology, increased investment in targeted therapies, and the continued development of precision oncology.

Oncology clinical trials remain central to evaluating the safety, efficacy, and clinical value of new cancer treatments. Research programs increasingly focus on targeted drugs, immunotherapies, cell therapies, and combination regimens designed for specific tumor characteristics and patient populations. As cancer treatment becomes more personalized, sponsors are adopting biomarker-driven protocols that improve patient stratification and help identify individuals most likely to respond to investigational therapies.

Technology and Trial Design Trends

Innovation in oncology clinical trial design is improving operational efficiency and supporting more patient-centered research. Adaptive protocols allow selected aspects of a study to be modified in response to interim findings, potentially accelerating decisions involving promising or ineffective treatment candidates. Decentralized and virtual trial models are also expanding access through telemedicine, remote monitoring, electronic data capture, and digital health technologies.

Artificial intelligence and machine learning are increasingly being applied to protocol development, patient identification, site selection, data analysis, and therapy assessment. At the same time, real-world evidence from electronic health records, registries, and other validated sources is complementing conventional clinical trial data and providing additional insight into treatment performance in routine clinical practice.

Immuno-oncology remains a major research priority. Clinical studies continue to evaluate checkpoint inhibitors, CAR-T cell therapies, and other immune-based approaches across multiple tumor types. Biomarker-driven studies are also gaining importance as pharmaceutical and biotechnology companies seek to improve response rates, optimize trial enrollment, and advance personalized cancer treatment strategies.

Market Growth Drivers

The oncology clinical trials market is benefiting from expanding global research networks and stronger collaboration among pharmaceutical companies, contract research organizations, academic institutions, healthcare providers, and patient advocacy groups. These partnerships are helping sponsors recruit broader patient populations, conduct multinational studies, and incorporate patient priorities into protocol design.

Additional market drivers include the growing cancer burden, increased research and development spending, advances in tumor profiling, and demand for specialized studies supporting targeted therapies. Wider adoption of remote trial technologies is also improving participant recruitment and study management, particularly in underserved or geographically dispersed communities.

Market Segmentation and Regional Outlook

  • Phase type: Phase I, Phase II, Phase III, and Phase IV clinical trials.
  • Study type: Interventional studies, observational studies, and expanded-access studies.
  • Geographic coverage: United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

The Phase I clinical trials segment is forecast to reach US$8.6 billion by 2032, growing at a CAGR of 7.2%. The Phase II segment is projected to expand at a CAGR of 5.8% over the analysis period.

Regionally, the United States oncology clinical trials market was valued at approximately US$3 billion in 2025. China is forecast to record a CAGR of 9.8% and reach US$3.6 billion by 2032, reflecting expanding research infrastructure, investment in biotechnology, and increasing participation in global drug development. The report also examines growth trends in Japan, Canada, Germany, Australia, India, South Korea, Brazil, Mexico, Saudi Arabia, the United Arab Emirates, and other key markets.

Report Scope and Strategic Value

The report provides independent analysis of annual market value and forecasts from 2025 through 2032. It assesses competitive conditions, regional dynamics, clinical trial phases, study types, growth opportunities, market restraints, and developments likely to influence oncology research strategy.

  • Detailed global and regional oncology clinical trials market forecasts.
  • Analysis of high-growth phases, study categories, and geographic markets.
  • Assessment of precision medicine, immuno-oncology, digital trials, and artificial intelligence.
  • Competitive intelligence covering prominent pharmaceutical and clinical research organizations.
  • Actionable insights supporting investment, market entry, partnership, and business development decisions.
  • Complimentary report updates for one year.

Companies Featured

  • AbbVie, Inc.
  • AstraZeneca PLC
  • Caidya
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • ICON plc
  • Medpace, Inc.
  • Merck & Co., Inc.
  • Novartis AG

Domain Expert Insights

The analysis incorporates perspectives from industry, enterprise, and academic experts to provide context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, corporate activity, conference sessions, keynote presentations, panel discussions, regulatory developments, institutional publications, annual reports, and validated company disclosures.

These inputs are synthesized to identify the direction of the oncology clinical trials market, the forces influencing change, and the developments most relevant to long-term strategy. The report also examines company-level activity and evaluates market share where it offers meaningful competitive insight. Because market structures vary across regions, the depth of market share analysis is aligned with the dynamics and availability of validated data in each geography.

Key Questions Addressed

  • How will the global oncology clinical trials market evolve through 2032?
  • Which factors are driving or restraining market growth?
  • Which clinical trial phases and study types offer the strongest growth potential?
  • How will regional market positions change during the forecast period?
  • Which companies are shaping the competitive landscape?
  • How are precision oncology, immunotherapy, digital technologies, and artificial intelligence transforming clinical research?

Key Attributes

Report Attribute Details
No. of Pages 283
Forecast Period 2025-2032
Estimated Market Value (USD) in 2025 $11.2 Billion
Forecasted Market Value (USD) by 2032 $17.2 Billion
Compound Annual Growth Rate 6.4%
Regions Covered Global


For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN20112026004107003653ID1111996723


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search